310 related articles for article (PubMed ID: 33973098)
21. Chemokines in neuroectodermal cancers: the crucial growth signal from the soil.
Gross N; Meier R
Semin Cancer Biol; 2009 Apr; 19(2):103-10. PubMed ID: 19015030
[TBL] [Abstract][Full Text] [Related]
22. Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.
Nazari A; Khorramdelazad H; Hassanshahi G
Int J Clin Oncol; 2017 Dec; 22(6):991-1000. PubMed ID: 29022185
[TBL] [Abstract][Full Text] [Related]
23. Synergy between coproduced CC and CXC chemokines in monocyte chemotaxis through receptor-mediated events.
Gouwy M; Struyf S; Noppen S; Schutyser E; Springael JY; Parmentier M; Proost P; Van Damme J
Mol Pharmacol; 2008 Aug; 74(2):485-95. PubMed ID: 18469140
[TBL] [Abstract][Full Text] [Related]
24. CCL2 in the Tumor Microenvironment.
O'Connor T; Heikenwalder M
Adv Exp Med Biol; 2021; 1302():1-14. PubMed ID: 34286437
[TBL] [Abstract][Full Text] [Related]
25. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo.
Loberg RD; Ying C; Craig M; Day LL; Sargent E; Neeley C; Wojno K; Snyder LA; Yan L; Pienta KJ
Cancer Res; 2007 Oct; 67(19):9417-24. PubMed ID: 17909051
[TBL] [Abstract][Full Text] [Related]
26. Estrogen receptor α promotes lung cancer cell invasion via increase of and cross-talk with infiltrated macrophages through the CCL2/CCR2/MMP9 and CXCL12/CXCR4 signaling pathways.
He M; Yu W; Chang C; Miyamoto H; Liu X; Jiang K; Yeh S
Mol Oncol; 2020 Aug; 14(8):1779-1799. PubMed ID: 32356397
[TBL] [Abstract][Full Text] [Related]
27. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
28. Beyond Cell Motility: The Expanding Roles of Chemokines and Their Receptors in Malignancy.
Morein D; Erlichman N; Ben-Baruch A
Front Immunol; 2020; 11():952. PubMed ID: 32582148
[TBL] [Abstract][Full Text] [Related]
29. CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases.
Craig MJ; Loberg RD
Cancer Metastasis Rev; 2006 Dec; 25(4):611-9. PubMed ID: 17160712
[TBL] [Abstract][Full Text] [Related]
30. Role of Tumor-Derived Chemokines in Osteolytic Bone Metastasis.
Coniglio SJ
Front Endocrinol (Lausanne); 2018; 9():313. PubMed ID: 29930538
[TBL] [Abstract][Full Text] [Related]
31. Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment.
Kfoury Y; Baryawno N; Severe N; Mei S; Gustafsson K; Hirz T; Brouse T; Scadden EW; Igolkina AA; Kokkaliaris K; Choi BD; Barkas N; Randolph MA; Shin JH; Saylor PJ; Scadden DT; Sykes DB; Kharchenko PV;
Cancer Cell; 2021 Nov; 39(11):1464-1478.e8. PubMed ID: 34719426
[TBL] [Abstract][Full Text] [Related]
32. Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases.
Tabariès S; Ouellet V; Hsu BE; Annis MG; Rose AA; Meunier L; Carmona E; Tam CE; Mes-Masson AM; Siegel PM
Breast Cancer Res; 2015 Mar; 17(1):45. PubMed ID: 25882816
[TBL] [Abstract][Full Text] [Related]
33. The Role of Inflammation in Breast and Prostate Cancer Metastasis to Bone.
Göbel A; Dell'Endice S; Jaschke N; Pählig S; Shahid A; Hofbauer LC; Rachner TD
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34064859
[TBL] [Abstract][Full Text] [Related]
34. Involvement of chemokine receptors in organ-specific metastasis.
Zlotnik A
Contrib Microbiol; 2006; 13():191-199. PubMed ID: 16627966
[TBL] [Abstract][Full Text] [Related]
35. ANGPTL2 increases bone metastasis of breast cancer cells through enhancing CXCR4 signaling.
Masuda T; Endo M; Yamamoto Y; Odagiri H; Kadomatsu T; Nakamura T; Tanoue H; Ito H; Yugami M; Miyata K; Morinaga J; Horiguchi H; Motokawa I; Terada K; Morioka MS; Manabe I; Iwase H; Mizuta H; Oike Y
Sci Rep; 2015 Mar; 5():9170. PubMed ID: 25773070
[TBL] [Abstract][Full Text] [Related]
36. Cytokines and Chemokines as Mediators of Prostate Cancer Metastasis.
Adekoya TO; Richardson RM
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32585812
[TBL] [Abstract][Full Text] [Related]
37. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
Khare T; Bissonnette M; Khare S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
[TBL] [Abstract][Full Text] [Related]
38. Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds.
Lança T; Costa MF; Gonçalves-Sousa N; Rei M; Grosso AR; Penido C; Silva-Santos B
J Immunol; 2013 Jun; 190(12):6673-80. PubMed ID: 23686489
[TBL] [Abstract][Full Text] [Related]
39. Acetyl-L-Carnitine downregulates invasion (CXCR4/CXCL12, MMP-9) and angiogenesis (VEGF, CXCL8) pathways in prostate cancer cells: rationale for prevention and interception strategies.
Baci D; Bruno A; Cascini C; Gallazzi M; Mortara L; Sessa F; Pelosi G; Albini A; Noonan DM
J Exp Clin Cancer Res; 2019 Nov; 38(1):464. PubMed ID: 31718684
[TBL] [Abstract][Full Text] [Related]
40. Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner.
Izhak L; Wildbaum G; Weinberg U; Shaked Y; Alami J; Dumont D; Friedman B; Stein A; Karin N
J Immunol; 2010 Jan; 184(2):1092-101. PubMed ID: 19995900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
